Fidelis Care covers most prescription drugs through a Preferred Drug List, but weight loss medications sit in a different category. Coverage depends on the plan type, the drug’s FDA-approved indication, and whether prior authorization criteria are met. For most Medicaid members, the answer is no.
GLP-1 drugs like Ozempic and Mounjaro are not covered for obesity on any Fidelis plan. FDA-approved weight management drugs like Wegovy and Saxenda may qualify on select non-Medicaid plans. Prior authorization is required, and clinical documentation of BMI and comorbidities is mandatory before approval.
This guide breaks down exactly which drugs Fidelis covers, which plans include weight loss benefits, what clinical criteria trigger approval, and what results members can realistically expect from prescription weight loss therapy.
Does Fidelis Care Cover Weight Loss Medication?
Fidelis Care does not cover most weight loss medications for the purpose of obesity treatment alone. Coverage depends on the specific plan type, the drug’s FDA-approved indication, and whether the prescription meets clinical criteria. Members on Medicaid plans face the strictest limits.
Fidelis Care’s pharmacy benefit follows New York State Medicaid guidelines. Those guidelines restrict weight loss drug coverage to cases where the medication treats an approved condition such as type 2 diabetes, not obesity by itself.
Coverage varies across plan types. Ambetter from Fidelis Care (a Qualified Health Plan) and Wellcare by Fidelis Care (Medicare) may include some FDA-approved weight loss drugs. Medicaid and Child Health Plus members have virtually no access to obesity medications through the formulary.
Plan Types and Weight Loss Drug Access:
| Plan Type | Weight Loss Drug Coverage | PA Required? |
| Medicaid (MMC) | No — diabetes indication only | N/A |
| HealthierLife (HARP) | No — diabetes indication only | N/A |
| Child Health Plus | No | N/A |
| Essential Plan | Limited — formulary restricted | Yes |
| Ambetter (QHP) | Yes — FDA-approved WM drugs | Yes |
| Wellcare Medicare | Possible — plan-specific | Yes |
Which Weight Loss Drugs Does Fidelis Sometimes Cover?
Fidelis Care may cover specific FDA-approved weight loss medications on select non-Medicaid plans, including Wegovy (semaglutide), Contrave, Saxenda, and Xenical. These drugs carry FDA approval specifically for chronic weight management and qualify under different coverage rules than diabetes-only medications.
Wegovy (semaglutide 2.4 mg) is distinct from Ozempic (semaglutide 1 mg). Wegovy holds FDA approval for weight management. Ozempic holds approval for type 2 diabetes. The FDA indication determines whether Fidelis will authorize coverage.
Contrave (naltrexone/bupropion) and Saxenda (liraglutide) are also on some Fidelis formularies for Qualified Health Plan members. Xenical (orlistat) is an older option that blocks dietary fat absorption and appears on some preferred drug lists. Prior authorization is typically required for all four.
FDA-Approved Weight Management Drugs:
- Wegovy (semaglutide 2.4 mg) — GLP-1 agonist, weekly injection
- Saxenda (liraglutide 3 mg) — GLP-1 agonist, daily injection
- Contrave (naltrexone/bupropion) — oral tablet, twice daily
- Xenical (orlistat 120 mg) — lipase inhibitor, oral with meals
- Zepbound (tirzepatide) — GIP/GLP-1 agonist, weekly injection
Which Fidelis Plan Includes Weight Loss Coverage?
Ambetter from Fidelis Care (Qualified Health Plan) is the plan most likely to include FDA-approved weight loss medications, subject to prior authorization and formulary tier placement. Medicare members under Wellcare by Fidelis Care may access some coverage depending on the specific drug benefit attached to their plan.
Medicaid Managed Care (MMC) and HealthierLife (HARP) members follow New York State’s Medicaid formulary. That formulary excludes weight loss drugs not approved for a comorbid condition. Child Health Plus and Essential Plan members face similarly narrow coverage.
How Does Fidelis Decide Whether to Cover a Drug?
Fidelis Care uses a Preferred Drug List (PDL) and a prior authorization process to determine whether a prescription qualifies for coverage. Drugs on the PDL are covered at standard cost-sharing. Drugs off the PDL require a Coverage Determination Request from the prescribing provider before Fidelis will approve payment.
The PDL ranks medications by therapeutic category. Tier placement affects member cost. Tier 1 generics carry the lowest out-of-pocket cost. Brand-name weight loss drugs typically land in higher tiers, with prior authorization as a mandatory gate.
What Is Prior Authorization and Do You Need It?
Prior authorization is a review process where Fidelis Care evaluates a medication request before approving coverage. The prescribing physician submits documentation that justifies the clinical need. Fidelis then verifies whether the drug matches its FDA-approved indication for the member’s documented diagnosis.
Most weight loss drugs require prior authorization regardless of plan type. Fidelis will review requests for GLP-1 agonists with particular scrutiny after a surge in off-label prescribing for obesity. Documentation of a qualifying diagnosis is not optional for approval.
What You Need for a PA Request:
- Current BMI documented by the provider
- ICD-10 diagnosis code for obesity (E66) or qualifying comorbidity
- History of lifestyle modification attempts (diet, exercise)
- FDA-approved indication matching the prescribed drug
- Completed Coverage Determination Request form from the prescriber
What Happens If Your Drug Is Not on the Formulary?
Members whose medication is not on the formulary can request a Coverage Determination, which is a formal appeal asking Fidelis to evaluate the drug outside standard formulary rules. The prescribing provider must submit clinical evidence explaining why the non-formulary drug is medically necessary.
A pharmacy can dispense a 72-hour emergency supply of a drug pending a prior authorization decision. This applies to drugs both on and off the PDL. The 72-hour supply buys time for the PA process to complete without leaving the member without medication.
Members who are denied coverage can file an appeal through Fidelis Care’s grievance process. Denials must include a written explanation. A second-level appeal or external review is available if the first-level denial stands.
Does Fidelis Cover Ozempic or Mounjaro for Weight Loss?
No. Fidelis Care does not cover Ozempic (semaglutide) or Mounjaro (tirzepatide) for weight loss or obesity treatment. Both drugs carry FDA approval for type 2 diabetes management. Fidelis restricts their coverage to that FDA-approved indication only.
Fidelis Care published an explicit notice addressing the surge in GLP-1 prescriptions. The plan stated it will actively monitor and review prior authorization requests for Ozempic and Mounjaro to ensure these drugs are used only per their FDA-approved indications.
Off-label prescribing of these medications for obesity has contributed to drug shortages for patients with type 2 diabetes who need them. Fidelis cited this shortage as a reason for tighter PA review. Members seeking GLP-1 therapy for obesity should ask providers about Wegovy or Zepbound, which carry weight management indications.
GLP-1 Coverage Comparison:
| Drug | FDA Indication | Covered for Weight Loss? |
| Ozempic (semaglutide 1mg) | Type 2 diabetes | No |
| Mounjaro (tirzepatide) | Type 2 diabetes | No |
| Wegovy (semaglutide 2.4mg) | Chronic weight management | Maybe (QHP/Medicare) |
| Zepbound (tirzepatide) | Chronic weight management | Maybe (QHP/Medicare) |
| Saxenda (liraglutide 3mg) | Chronic weight management | Maybe (QHP/Medicare) |
Can You Get a GLP-1 Drug Covered for Obesity?
Yes, but only with the right prescription. Wegovy is the semaglutide formulation FDA-approved for chronic weight management, and it may qualify for coverage on some Fidelis plans where Ozempic does not. Zepbound (tirzepatide) holds the same weight management approval that Mounjaro lacks.
Coverage for Wegovy or Zepbound still requires prior authorization on most plans. A body mass index (BMI) of 30 or higher, or a BMI of 27 with at least one weight-related comorbidity, is the standard clinical threshold for GLP-1 weight management drugs. Providers must document this in the PA submission.
What Are the Benefits of Weight Loss Medication?
Prescription weight loss medications reduce appetite, slow gastric emptying, and alter metabolic signaling in ways that diet and exercise alone cannot reliably replicate. FDA-approved options produce clinically significant weight loss in randomized controlled trials, with outcomes far exceeding placebo or lifestyle intervention alone.
GLP-1 receptor agonists like semaglutide and tirzepatide reduce hunger hormones and increase satiety signals. Trial participants on semaglutide 2.4 mg lost an average of 14.9% of body weight over 68 weeks. Tirzepatide produced average losses of up to 22.5% in the SURMOUNT-1 trial.
Beyond the scale, weight loss medication improves cardiovascular risk markers. Semaglutide reduced major adverse cardiovascular events by 20% in the SELECT trial. Lowering body weight by 5% to 10% improves blood pressure, blood sugar control, and lipid profiles in most patients.
Key Benefits of Weight Loss Medication:
- Significant appetite suppression through hormonal signaling
- Clinically proven 5% to 22% total body weight loss
- Reduced cardiovascular event risk (20% reduction with semaglutide)
- Improved blood sugar, blood pressure, and lipid levels
- Greater long-term outcomes than lifestyle intervention alone
How Much Weight Can You Lose With Prescription Drugs?
Clinical outcomes show that FDA-approved weight loss medications produce average losses of 5% to 22% of body weight depending on the drug, dose, and duration of treatment. Results vary by individual, but most patients see measurable changes within 12 to 16 weeks of starting therapy.
Older medications like Xenical (orlistat) produce more modest results, averaging 5% to 7% total body weight loss over one year. Newer GLP-1 and GIP/GLP-1 agonists produce two to four times more loss. The gap reflects fundamentally different mechanisms of action.
What Are the Risks of Weight Loss Medication?
Weight loss medications carry side effects that range from mild gastrointestinal symptoms to rare but serious complications including pancreatitis and thyroid tumors. GLP-1 agonists commonly cause nausea, vomiting, diarrhea, and constipation, particularly in the first weeks of dose escalation.
Contrave (naltrexone/bupropion) carries a black box warning for suicidal thoughts due to the bupropion component. Saxenda shares the thyroid tumor risk seen across the GLP-1 class in animal studies. Xenical causes oily stools, fecal urgency, and fat-soluble vitamin deficiencies with prolonged use.
Cardiovascular monitoring is important for patients with pre-existing heart conditions. Some weight loss drugs raise heart rate. Patients using GLP-1 drugs who develop persistent severe abdominal pain should seek immediate evaluation for pancreatitis.
Common Side Effects by Drug:
- GLP-1 agonists (Wegovy, Saxenda): nausea, vomiting, diarrhea, constipation
- Contrave: headache, dry mouth, insomnia, elevated blood pressure
- Xenical: oily stools, fecal urgency, fat-soluble vitamin depletion
- All classes: gallstone formation risk with rapid weight loss
Who Should Avoid Weight Loss Drugs?
Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use GLP-1 receptor agonists due to a documented thyroid tumor risk observed in animal studies. Pregnant or breastfeeding individuals must avoid all prescription weight loss medications.
Patients with a history of eating disorders should discuss risks carefully with a provider before starting any appetite-suppressing medication. Those with gallbladder disease face elevated gallstone risk on GLP-1 therapy due to reduced gallbladder motility. Rapid weight loss accelerates gallstone formation in susceptible patients.
What Are the Requirements to Get Weight Loss Drugs Covered?
Most insurers, including Fidelis Care, require documented clinical criteria including a qualifying BMI and at least one weight-related comorbidity before approving weight loss medication coverage. A BMI of 30 kg/m squared (kg/m2) or higher qualifies on its own. A BMI of 27 kg/m2 with conditions such as hypertension, type 2 diabetes, or sleep apnea also qualifies.
The prescribing physician must document prior attempts at diet and exercise modification. Fidelis and similar plans want evidence that lifestyle intervention was attempted before medication is added. Without that documentation, prior authorization requests are more likely to be denied.
Do You Need a Doctor’s Diagnosis to Qualify?
Yes. A physician must document a diagnosis of obesity or overweight with comorbidity in the patient record before Fidelis will consider a prior authorization request for weight loss medication. Self-reported weight or a verbal statement from the patient does not satisfy the clinical documentation requirement.
A formal obesity diagnosis uses the ICD-10 code E66 and its subcategories. The provider’s notes must include current BMI, documented comorbidities, and a history of non-pharmacological treatment. Submitting incomplete documentation is the most common reason prior authorization requests are denied on the first attempt.
How Long Does Weight Loss Medication Take to Work?
Most patients begin to see measurable weight loss within four to eight weeks of starting prescription weight loss therapy at the target maintenance dose. GLP-1 medications use a gradual dose escalation schedule that takes several weeks to reach the full therapeutic dose, which delays peak efficacy.
Semaglutide (Wegovy) follows a 16-week escalation schedule. The starting dose of 0.25 mg weekly increases every four weeks until reaching 2.4 mg. Weight loss accelerates after reaching the maintenance dose. Full clinical effect across a 68-week trial averaged 14.9% total body weight loss.
What Results Can You Expect?
Realistic outcomes for most patients on FDA-approved weight loss medication range from 5% to 22% total body weight loss over six to eighteen months, depending on the drug and adherence. A 5% loss from a starting weight of 100 kilograms (220 pounds) is 5 kilograms (11 pounds), which already produces measurable health improvements.
Weight loss slows or plateaus after the first six to twelve months on most drugs. The body adapts to the lower caloric intake and adjusts energy expenditure downward. Continued adherence maintains the loss even when active loss slows. Stopping medication typically results in partial weight regain within a year.
Combining medication with structured dietary support accelerates results. Ready to speed things up? Get a proven weight loss plan built around these exact principles.
Want Your Free Eat Proteins Weight Loss Plan?
You’ve got the facts. Now you need the plan. The free Eat Proteins plan gives you a structured roadmap built around high-protein meals, sustainable calorie targets, and the exact dietary habits that support medication-free or medication-assisted weight loss. Our nutritionists at Eat Proteins designed it for real people with real schedules and real goals.
Don’t figure this out alone. The plan is free, it’s specific, and it lands straight in your inbox. Miss it, and you’re back to guessing. Grab it and you’ll have everything you need to start this week.